1 Dietrich CG, Geier A, Oude Elferink RPJ.ABC of oral bioavailability:transporters as gatekeepers in the gut[J].Gut, 2003;52:1788-1795.
2 Schinkel AH, Jonker JW.Mammalian drug efflux transporters of the ATP binding cassette (ABC)family:an overview[J].Adv Drug Deliv Rev, 2003;55:3-29.
3 Sauna ZE, Ambudkar SV.Characterization of the catalytic cycle of ATP hydrolysis by human P-glycoprotein.The two ATP hydrolysis events in a single catalytic cy cle are kinetically similar but affect different functional outcomes[J].J Biol Chem, 2001;276:11653-11661.
4 Litman T, Skovsgaard T, Stein WD.Pumping of Drugs by PGlycoprotein: A Two-Step Process[J]? J Pharmacol Exp Ther, 2003;307:746-753.
5 Schinkel AH, Wagenaar E, van Deemter L, et al.Absence of the mdr1a P-Gly coprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A [J].J Clin Invest, 1995;96:1698-1705.
6 Schinkel AH, Smit JJ, van Tellingen O, et al.Disruption of the mouse mdr1a P-gly coprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs[J]. Cell, 1994;77:491-502.
7 Chen C, Hanson E, Watson JW, et al.P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists[J].Drug Metab Dispos, 2003;31:312-318.
8 Liu XD, Liu GQ.P-Glycoprotein regulated transport of glutamate at bllod brain barrier[J].Act Pharmacol Sin, 2001;22: 111-116.
9 Vogelgesang S, Cascorbi I, Schroeder E, et al.Deposition of Alzheimer's bata-amyloid is inversely correlated with P-gly coprotein expression in the brains of elderly nondemented humans [J].Pharmacogenetics, 2002;12:535-541.
10 Lam FC, Liu RH, Lu PH, et al.(-Amy loid effux mediated by p-glycoprotein[J].J Neurochem, 2001;76:1121-1128.
11 Bardelmeijer HA, Bardelmeijer HA, OuwehandM, et al.Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice[J].Invest New Drugs, 2004;22:219-229.
12 Hu JH, Liu XD, Xie L, et al.Possible multiple transporters were involved in hepatobiliary excretion of antofloxacin in rats [J].Xenobiotica, 2007;37:579-591.
13 Illmer T, Schaich TM, Platzbecker U, et al.P-glycoproteinmediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate [J].Leukemia, 2004;18:401-408.
14 Zhang L, Liu XD, Xie L, et al.P-glycoprotein restricted transport of nimodipine across blood-brain barrier [J].Acta Pharmacol Sin, 2003;24:903-906.
15 Liu XD, Zhang L, Xie L, et al.Effect of P-gly coprotein inhibitors erythromycin and cyclosporin A on brain pharmacokinetics of nimodipine in rats[J].Eur J Drug Metab Pharmacokinet, 2003;28:309-313.
16 Liu XD, Pan GY, Xie L, et al.Cyclosporin A enhanced protection of nimodipine against brain damage induced by hypoxiaischemia in mice and rats[J].Acta Pharmacol Sin, 2002;23: 225-229.
17 Löscher W, Potschka H.Role of multidrug transporters in pharmacoresistance to antiepileptic drugs[J].J Pharmacol Exp Ther, 2002;301:7-14.
18 Brandt C, Bethmann K, Gastens AM, et al.The multidrug transporter hypothesis of drug resistance in epilepsy:Proof-ofprinciple in a rat model of temporal lobe epilepsy[J].Neurobiol Dis, 2006;24:202-211.
19 Liu XD, Yang ZH, Yang JS, et al.Increased P-glycoprotein expression and decreased phenobarbital distribution in the brain of pentylenetetrazole-kindled rats[J].Neuropharmacol, 2007; in press.
20 Chin KV, Tanaka S, Darlington G, et al.Heat shock and arsenite increase expression of the multidrug resistance (mdr1) gene in human renal carcinoma cells[J].J Biol Chem, 1989; 265:221-226.
21 Goralski KB, Hartmann G, Piguette-MillerM, et al.Downregulation of mdr1a expression in the brain and liver during CNS inflammation alters the in vivo disposition of digoxin[J].Br J Pharmacol, 2003, 139:35-48.
22 Liu HY, Zhang DM, Xu X, et al.Attenuated function and expression of P-glycoprotein at blood-brain barrier and increased brain distribution of phenobarbital in streptozotocin-induced diabetic mice[J].Eur J Pharmacol, 2007;561:226-232.
23 Liu HY, Liu XD.Impaired Function and Expression of P-glycoprotein in blood-brain barrier of streptozotocin-induced diabetic rats[J].Brain Res, 2006;1123:245-252.
24 Felix RA, Barrand MA.P-glycoprotein expression in rat brain endothelial cells:evidence for regulation by transient oxidative stress[J].J Neurochem, 2002;80:64-72.
25 Kondratov RV, Komarov PG, Becker Y, et al.Small molecules that dramatically alter multidrug resistance phenotype by modulating the substrate specificity of P-glycoprotein[J].Proc Natl Acad Sci USA, 2001;98:14078-14083.
26 Ouyang H, Yang JZ, Borchardt RT.Bidirectional transport of rhodamine 123 and Hoechst 33342, fluorescence probes of the binding sites on P-glycoprotein, across MDCK-mdr1 cell monolayers[J].J Pharm Sci, 2004;93:1185-1194.
27 Sun JJ, Xie L, Liu XD.Transport of carbamazepine and drug interactions at the blood-brain barrier[J].Acta Pharmacol Sin, 2006;27:249-253.
28 Zhang DM, Liu HY, Xie L, et al.Effect of baicalin and berberine on transport of nimodipine on primary cultured rat brain microvascular endothelial cells[J].Acta Pharmacol Sin, 2007; 28:573-578.
29 Ding S, Chamberlain M, McLaren A, et al.Cross-talk between signalling pathway s and the multidrug resistant protein mdr-1[J].Br J Cancer, 2001;85:1175-1184.
30 Karwatsky J, LincolnMC, Georges E.A mechanism for P-glycoprotein-mediated apoptosis as revealed by verapamil hypersensitivity[J].Biochem, 2003;42:12163-12173.
31 Castagne V, Bonhomme-Faivre L, Urien S, et al.Effect of recombinant interleukin-2 pretreatment on oral and intravenous digoxin pharmacokinetics and P-glycoprotein activity in mice [J].Drug Metab Dispos, 2004;32:168-171.
32 Kawaguchi H, Matsui Y, Watanabe Y, et al.Effect of interferon-γ on the pharmacokinetics of digoxin, a P-glycoprotein substrate, intravenously injected into the mouse[J].Pharmacol Exp Ther, 2004;308:91-96.
33 Achira M Totsuka R, Fujimura H, et al.Tissue-specific regulation of expression and activity of P-glycoprotein in adjuvant arthritis rats[J].Eur J Pharma Sci, 2002;16:29-36.
34 Ando H, Nishio Y, Ito K, et al.Effect of Endotoxin on P-glycoprotein-mediated biliary and renal excretion of rhodamine-123 in rats[J].Antimicrob Agents Chemother, 2001;45:3462-3467.
35 Goralski KB, Hartmann G, Piquette-Miller M, et al.Downregulation of mdr 1a expression in the brain and liver during CNS inflammation alters the in vivo disposition of digoxin[J]. Brit J Pharmacol, 2003;139:35-48.
36 Hartz AM, Bauer B, Fricker G, et al.Rapid modulation of Pgly coprotein-mediated transport at the blood-brain barrier by tumor necrosis factor-alpha and lipopolysaccharide[J].Mol Pharmacol, 2006;69:462-470.
37 Theron D, de Lagerie S B, Tardivel S, et al.Influence of tumor necrosis factor-a on the expression and function of P-glycoprotein in an immortalised rat brain capillary endothelial cell line, GPNT[J].Biochem Pharmacol, 2003;66:579-587.
38 Ziemann C, Schafer D, Rudell G, et al.The cyclooxygenase system participates in functional mdr1b overexpression in primary rat hepatocyte cultures[J].Hepatology, 2002;35:579-588.
39 Comerford KM, Wallace TJ, Karhausen J, et al.Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (mdr1)gene[J].Cancer Res, 2003;62:3387-3394.
40 Ledoux S, Yang R, Friedlander G, et al.Glucose depletion enhances P-glycoprotein expression in hepatoma cells:role of endoplasmic reticulum stress response[J].Cancer Res, 2003; 63:7284-7290.
41 Handschin C, Meyer UA.Induction of drug metabolism:the role of nuclear receptors[J].Pharmacol Rev, 2003;55:649-673. |
